Insulet faces securities class action over alleged disclosure failures

Insulet Corporation is facing a securities class action on behalf of investors who purchased or otherwise acquired the company’s securities between February 21, 2025 and May 26, 2026. The complaint alleges Insulet failed to disclose defective manufacturing controls and procedures, creating a foreseeable heightened risk that one or more products could violate applicable safety regulations or pose a risk of injury, and that public statements about the business were therefore materially false or misleading during the class period. The case points to two 2026 product-correction disclosures: a March 12, 2026 voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, followed by a May 26, 2026 correction involving specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue that could result in insulin under-delivery. Insulet shares fell 6.9% to $219.84 on March 13, 2026 after the first disclosure and 5.1% to $146.01 on May 27, 2026 after the second. Investors seeking to serve as lead plaintiff must move by August 31, 2026.